TABLE 1.
.Plasma and Urine CYP450 Metabolites in AUDA-Treated Rats
| Oxylipid Metabolites | Control Plasma | AUDA Plasma | Control Urine | AUDA Urine |
|---|---|---|---|---|
| EPOMEs (pmol/mL) | 292.5 ± 26.2 | 290.7 ± 14.4 | 2568 ± 625 | 2090 ± 131 |
| DHOMEs (pmol/mL) | 56.7 ± 5.7 | 52.9 ± 6.9 | 1,170 ± 33 | 722 ± 52 |
| EPOME:DHOME ratio | 5.2 | 5.5 | 2.2 | 2.9 |
| EETs (pmol/mL) | 95.0 ± 20.7 | 72.9 ± 21.1 | 25.7 ± 1.12 | 28.7 ± 3.91 |
| DHETs (pmol/mL) | 30.0 ± 1.8 | 23.9 ± 2.1 | 30.8 ± 9.1 | 20.9 ± 0.8 |
| EET:DHET ratio | 3.2 | 3.1 | 0.8 | 1.4 |
| 12,13-EPOME | 89 ± 2% | 91 ± 1% | 75 ± 1% | 76 ± 1% |
| 9,10-EPOME | 11 ± 2% | 9 ± 1% | 25 ± 1% | 24 ± 1% |
| 12,13-DHOME | 58 ± 3% | 46 ± 1% | 74 ± 2% | 72 ± 1% |
| 9,10,-DHOME | 42 ± 3% | 54 ± 1% | 26 ± 2% | 28 ± 1% |
| 14,15-EET | 39 ± 7% | 40 ± 4% | 57 ± 1% | 55 ± 2% |
| 11,12-EET | 14 ± 1% | 16 ± 1% | 43 ± 1% | 45 ± 3% |
| 8,9-EET | 24 ± 8% | 17 ± 6% | 0 ± 0% | 0 ± 0% |
| 5,6-EET † | 24 ± 1% | 27 ± 2% | ND | ND |
| 14,15-DHET | 8 ± 1% | 10 ± 1% | 14 ± 2% | 12 ± 1% |
| 11,12-DHET | 7 ± 2% | 8 ± 1% | 0 ± 0% | 0 ± 0% |
| 8,9-DHET | 6 ± 1% | 6 ± 1% | 0 ± 0% | 0 ± 0% |
| 5,6-DHET | 79 ± 3% | 76 ± 1% | 86 ± 2% | 88 ± 1% |
Values are mean ± SE.
†
5,6-EET recoveries with the implemented procedure are roughly 25%. Loss of this compound is apparently through internal cyclization to the 5,6-delta lactone, not hydrolysis to the 5,6-DHET (29). “%” indicates the percentage of specific EPOMEs, DHOMEs, EETs, and DHETs in total EPOMEs, DHOMEs, EETs, and DHETs respectively.
Abbreviations: SHRSP, stroke-prone spontaneously hypertensive rats; EET, epoxyeicosatrienoic acid; DHET, dihydroxyeicosatrienoic acids; AUDA, adamantyl dodecanoic acid; EPOME, epoxyoctadecanoic acid; DHOME, dihydroxyoctadecanoic acid.